ADVAGENE BIOPHARMA CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 26.95 TWD | +0.94% |
|
+8.02% | +6.10% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 1,146 | 884.3 | 1,467 | 2,396 | 1,479 | 1,355 |
| Enterprise Value (EV) 1 | 833.6 | 646.3 | 1,199 | 2,176 | 1,378 | 1,230 |
| P/E ratio | -8.23 x | -9.65 x | -20.9 x | -25.6 x | -12.5 x | -13.9 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - |
| EV / EBITDA | -6.86 x | -6.85 x | -17 x | -24.4 x | -12 x | -13.8 x |
| EV / FCF | -11.4 x | -14.2 x | -31.5 x | -39.1 x | -18.1 x | -28 x |
| FCF Yield | -8.77% | -7.02% | -3.18% | -2.56% | -5.52% | -3.57% |
| Price to Book | 3.3 x | 3.27 x | 4.92 x | 9.63 x | 11.2 x | 9.69 x |
| Nbr of stocks (in thousands) | 44,059 | 44,216 | 44,387 | 49,142 | 49,292 | 53,349 |
| Reference price 2 | 26.00 | 20.00 | 33.05 | 48.75 | 30.00 | 25.40 |
| Announcement Date | 4/17/19 | 4/8/20 | 4/21/21 | 4/15/22 | 4/25/23 | 4/11/24 |
1TWD in Million2TWD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales | - | - | - | - | - | - |
| EBITDA 1 | -121.5 | -94.29 | -70.41 | -89.24 | -115.2 | -89.32 |
| EBIT 1 | -125.7 | -98.84 | -75.79 | -94.43 | -119.8 | -93.34 |
| Operating Margin | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -111.3 | -91.62 | -70.16 | -92.69 | -118.4 | -92.11 |
| Net income 1 | -111.3 | -91.62 | -70.16 | -92.69 | -118.4 | -92.11 |
| Net margin | - | - | - | - | - | - |
| EPS 2 | -3.157 | -2.073 | -1.583 | -1.902 | -2.399 | -1.828 |
| Free Cash Flow 1 | -73.14 | -45.36 | -38.09 | -55.71 | -76.12 | -43.87 |
| FCF margin | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 4/17/19 | 4/8/20 | 4/21/21 | 4/15/22 | 4/25/23 | 4/11/24 |
1TWD in Million2TWD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 312 | 238 | 268 | 220 | 101 | 125 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -73.1 | -45.4 | -38.1 | -55.7 | -76.1 | -43.9 |
| ROE (net income / shareholders' equity) | -39.7% | -29.6% | -24.6% | -33.8% | -62.1% | -67.8% |
| ROA (Net income/ Total Assets) | -26.9% | -19.4% | -15.9% | -20.5% | -37.3% | -40.4% |
| Assets 1 | 414.6 | 473.1 | 441 | 452.8 | 317.2 | 228 |
| Book Value Per Share 2 | 7.870 | 6.110 | 6.720 | 5.060 | 2.670 | 2.620 |
| Cash Flow per Share 2 | 0.3100 | 0.2800 | 2.740 | 0.2900 | 0.3600 | 1.220 |
| Capex 1 | 0.34 | 0.04 | 0.63 | 0.52 | 0.21 | - |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 4/17/19 | 4/8/20 | 4/21/21 | 4/15/22 | 4/25/23 | 4/11/24 |
1TWD in Million2TWD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +6.10% | 44.56M | |
| +21.76% | 47.9B | |
| +46.62% | 41.42B | |
| -2.18% | 40.7B | |
| -6.20% | 28.92B | |
| +10.19% | 25.55B | |
| -20.87% | 19.27B | |
| -0.32% | 12.15B | |
| +31.04% | 12.14B | |
| -0.47% | 11.99B |
- Stock Market
- Equities
- 6709 Stock
- Financials Advagene Biopharma Co., Ltd.